Aquestive Therapeutics (NASDAQ:AQST) Posts Earnings Results

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.08), Zacks reports. The company had revenue of $12.05 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter in the previous year, the company earned $0.11 earnings per share.

Aquestive Therapeutics Stock Up 0.6 %

Shares of AQST stock traded up $0.02 during trading hours on Wednesday, reaching $3.22. 941,532 shares of the stock traded hands, compared to its average volume of 2,214,790. The firm has a market capitalization of $293.15 million, a PE ratio of -7.67 and a beta of 2.95. Aquestive Therapeutics has a 1-year low of $1.25 and a 1-year high of $6.23. The business has a fifty day moving average price of $4.15 and a 200 day moving average price of $2.98.

Analysts Set New Price Targets

AQST has been the topic of a number of recent research reports. JMP Securities lifted their price target on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Friday, March 15th. Piper Sandler initiated coverage on shares of Aquestive Therapeutics in a research report on Thursday, April 11th. They set an "overweight" rating and a $10.00 price target on the stock. Leerink Partnrs raised shares of Aquestive Therapeutics to a "strong-buy" rating in a research report on Friday, May 10th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, May 9th. Finally, Raymond James began coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They set an "outperform" rating and a $7.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $8.00.

Insider Activity at Aquestive Therapeutics

In related news, insider Alexander Mark Schobel sold 50,000 shares of the company's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 984,476 shares in the company, valued at approximately $5,906,856. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.39% of the stock is owned by insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.